Abstract: The present invention relates to novel coating compositions for application to solid dosage forms such as tablets or caplets, solid dosage forms coated with the composition, and methods of preparing said coating compositions.

Abstract: Methods for evaluating and treating patients for dysphagia are provided. In a general embodiment, the method comprises screening the patient for dysphagia symptoms, diagnosing and categorizing the dysphagia if the patient exceeds a threshold of dysphagia symptoms, choosing the proper dysphagia treatment product based the patient's dysphagia, and giving the patient preparation instructions for the dysphagia treatment product.

Abstract: The invention provides liquid or semi-solid pharmaceutical compositions for topical administration comprising a semifluorinated alkane. The compositions are useful for the delivery of active ingredients into the deep layers of the skin or skin appendages. Various active ingredients may be incorporated, such as immunosuppressants, antiinfectives, antifungal agents, antiinflammatory agents, and retinoids.

Abstract: A solid pharmaceutical dosage form providing improved oral bioavailability is disclosed for inhibitors of HIV protease. In particular, the dosage form comprises a solid dispersion of at least one HIV protease inhibitor and at least one pharmaceutically acceptable water-soluble polymer and at least one pharmaceutically acceptable surfactant, said pharmaceutically acceptable water-soluble polymer having a Tg of at least about 50° C. Preferably, the pharmaceutically acceptable surfactant has an HLB value of from about 4 to about 10.

Abstract: The present invention provides a cleansing composition for skin or hair which can provide a good rinse feel, give good combability and softness from rinsing to drying when the cleansing composition is applied to hair, and give good moist feeling to skin when the cleansing composition is applied to skin. The cleansing composition for skin or hair is a cleansing composition comprising an internal olefin sulfonate (A) having 12 or more and 24 or less carbon atoms.

Abstract: The present invention relates to an adjuvant for enhancing the activity of pesticides comprising a polar solvent and a phosphate ester of the formula (A) (as described hereinbelow), it being possible for the phosphate ester of the formula (A) to be present as the free acid and/or as a salt, and where the polar solvent is miscible with water in any ratio and has a flash point of above 60° C.

Abstract: A method of preparing a pharmaceutical formulation comprises providing a solution comprising a first solvent, a second solvent, an active agent, and an excipient. The second solvent is less polar than the first solvent and the excipient is more soluble in water than the active agent. The first and second solvents are removed from the solution to produce particles comprising the active agent and the excipient. In one version, the excipient comprises an amino acid and/or a phospholipid. A pharmaceutical formulation made by a version of the invention comprises particles comprising an active agent and an excipient which at least partially encapsulates the active agent, wherein the excipient is more soluble in water than the active agent.

Abstract: The subject application provides for an emulsion comprising an amount of a perfluorocarbon liquid dispersed as particles within a continuous liquid phase, wherein the dispersed particles have a monomodal particle size distribution and uses thereof. The subject application also provides for a method of manufacturing a perfluorocarbon emulsion, a process for preparing a pharmaceutical product containing a PFC emulsion and a process for validating a batch of an emulsion for pharmaceutical use.

Abstract: The present disclosure relates generally to compositions for cosmetic or pharmaceutical application. The compositions include a carrier and rheology modulators.

Abstract: The invention relates to a composition comprising, in a physiologically acceptable oily medium, 4-(3-ethoxy-4-hydroxyphenyl)-2-butanone and a solvent with solubility parameters in the Hansen solubility space such that 4.5<?a<7 and 14<?d<22. Use for caring for, making up and cleansing keratin materials.

Abstract: In one aspect, an epidermal coolant includes a porous material and a phase change material retained in the porous material. The phase change material has a melting point between about 0-degrees Celsius and about 65-degrees Celsius and is retained in the porous material when the phase change material is in either the solid or liquid phase. In another aspect, an epidermal coolant dispensable by an aerosol container includes a phase change material that changes phase between about 28-degrees and 40-degrees Celsius. The coolant also includes a solvent in which the phase change material is dissolved and a surfactant. The coolant may further include a propellant to express the product from the aerosol container.

Abstract: The present invention relates generally to compositions or formulations for transdermal or transmucosal administration of anti-cholinergic agents such as oxybutynin. The invention utilizes a novel delivery vehicle and is a substantially malodorous-free and irritation free transdermal formulation which is substantially free of long chain fatty alcohols, long-chain fatty acids, and long-chain fatty esters. A method is disclosed for administering such formulations to a person in need thereof while reducing the incidences of peak concentrations of drug and undesirable side effects associated with oral anti-cholinergics.

Abstract: The invention provides novel Zr MOFs, in particular compounds having a surface area of at least 1020 m2/g or if functionalized, having a surface area of at least 500 m2/g.

Abstract: A fluid carrier comprises first and second substantially immiscible liquids. The first liquid is an open-chain silicone oil of the formula [(CH3)3Si—O]—[(CH2)2Si—O]n—[Si(CH3)3]. The second liquid is a polar lipid material. The first and second liquids are capable of forming an unstable dispersion. The unstable dispersion can be stabilized by adding a powderous solid insoluble in the liquids. The powderous solid is selected from pharmacologically active agent, pharmaceutical excipient, and their mixtures. The stabilized dispersion is of a creamy or ointment-like or mouldable form, and can be filled into capsules or moulded into tablets so as to be fit for peroral administration.

Abstract: The present invention relates to synthetic lung surfactant compositions that contain one or more of phospholipase-resistant phospho-glycerol derivatives, phospholipase-resistant phospho-choline derivatives, and surface active proteins or peptides, more preferably a combination of at least two or all three of these materials. Novel phospholipase-resistant phospho-glycerol derivatives, phospholipase-resistant phospho-choline derivatives, and surface active peptides are also disclosed herein. Uses of the surfactant compositions of the present invention to treat endogenous surfactant dysfunctional or deficient lung tissue, to prepare synthetic peptides for use in the surfactant compositions, and to deliver therapeutic agents are also disclosed.

Abstract: Anti-cancer coating compositions comprising 3-hydroxymethyl-5-aziridinyl-1-1-methyl-2-[1H-indole-4,7-dione]propenol (E09) are disclosed. More specifically, the coating compositions comprise EO9 and a formulation vehicle. The formulation vehicle improves the solubility and stability of EO9. Additionally, the coating compositions can include coating agents that provide better adhesion of the coating composition to the bladder wall during intravesical delivery of the coating composition.

Abstract: Disclosed are gel compositions suitable for the topical administration of an active compound having poor solubility and skin penetration, for example, of a COX-2 inhibitor compounds, processes of preparation thereof and methods of use thereof for the treatment of indications treatable by the active compound.

Abstract: A thiol-yne polymeric material and methods for producing said polymers are disclosed. The material is produced by the radically mediated polymerization of monomers having alkyne and thiol functional groups. The alkyne moiety, internal or terminal, may react with one or two thiols. Degradable monomers may be used to form degradable polymers.

Abstract: The invention relates to a composition comprising a oil-soluble polar modified polymer and a hyperbranched polyol.

Abstract: Provided are personal care compositions comprising a first surfactant comprising sodium lauryl sulfate and a second surfactant having a structure represented by wherein each a has a value of about 1 to about 110, b has a value of about 16 to about 70, and at least one R group is SO3, and the other R group is SO3 or hydrogen. Also provided are methods of producing personal care compositions and methods of ameliorating skin or mucosal membrane irritation due to sodium lauryl sulfate.

Abstract: An aqueous disinfecting solution having a pH from about 0.5 to about 6 and consisting essentially of hydrogen peroxide in a concentration from about 0.05 to about 8 w/w % of the total solution; at least one anionic surfactant in a concentration from about 0.02 to about 8 w/w % of the total solution, selected from sulfonated C12 to C22 carboxylic acids and alkali metal, ammonium, calcium and magnesium salts thereof; naphthalene sulfonic acids and alkali metal, ammonium, calcium and magnesium salts thereof; C8 to C22 alkyl sulfonic acids and alkali metal, ammonium, calcium and magnesium salts thereof; and alkyl or alkenyl esters or diesters of sulfosuccinic acids in which the alkyl or alkenyl groups independently contain from six to eighteen carbon atoms and alkali metal, ammonium, calcium and magnesium salts thereof; and benzyl alcohol in a concentration from about 0.1 to about 10 w/w % of the solution.

Abstract: The invention relates to an aqueous transparent oil-in-water emulsion comprising a carotenoid and a process for producing said emulsion.

Abstract: The present invention is directed to a novel fragrance compound of octahydro-4,7-methano-1H-indene-5-acetaldehyde, octahydro-6-methyl-4,7-methano-1H-indene-5-carboxaldehyde, or a mixture thereof.

Abstract: A personal care composition includes at least one end-functionalized ionic silicone and at least one film-forming agent.

Abstract: The present invention relates to compositions including anhydrous compositions which include a dimethicone crosspolymer and/or dimethicone elastomer gum and one or more skin care products which may include retinoic acid, retinoic acid derivatives, retinal, retinol and/or retinyl esters, and methods of making, storing, and using such compositions.

Abstract: A composition which comprises a biologically active agent and a polymer that exhibits a reverse thermal gelation at a physiological temperature, in a carrier, and in which the active agent is in an undissolved form is disclosed herein. Further disclosed herein are methods utilizing the compositions for treating subjects, including non-human subjects, as well as kits for preparing and using a composition. The composition is preferably a sustained release formulation, and is particularly useful for treating animals, where single-dose treatment is desired.

Abstract: The present invention provides micelles having an anthracycline encapsulated therein, the micelles comprising a multiblock copolymer. The invention further provides methods of preparing and using said micelles, and compositions thereof.

Abstract: The present invention concerns a compound of formula (I), in the form of any one of its stereoisomers or a mixture thereof, and wherein the dotted line represents a carbon-carbon single or double bond; as well as its use as perfuming ingredient.

Abstract: According to the present invention, a substituted aromatic compound represented by the following general formula (I) is provided. In general formula (I), A1, A2, and A3 each independently represent an aryl group substituted by a hydrophilic group.

Abstract: The present invention is related to a mesoscale colloidal particle including a hydrophobe-rich core surrounded by hydrogen bonded outer shell. The outer shell includes water and at least one hydrotrope wherein the hydrotrope molecules form hydrogen bonds with water molecules. The invention is also related to an aqueous solution including at least one mesoscale colloidal particle as well as methods of making and using such mesoscale colloidal particles and their solutions.

Abstract: The present invention provides a cosmetic exhibiting superior feeling to the touch and a superior uniformity using a novel organopolysiloxane. The cosmetic contains a liquid organopolysiloxane having fluidity at 25° C. and having a crosslinked three-dimensional network structure. The aforementioned liquid organopolysiloxane has a loss factor, tan ?, at a shear frequency of 10 Hz, which is 1 or more.

Abstract: Disclosed is a stable liquid formulation for parenteral injection comprising a biocompatible non-aqueous solvent and a small molecule drug, or a salt thereof, solubilized within the non-aqueous solvent, wherein the liquid formulation comprises less than 10% by weight residual water, and wherein the volume of the liquid formulation to be parenterally injected is from 0.1 ?l to 3 ml.

Abstract: A pharmaceutical composition comprising: a) a 5-HT1 agonist; b) an NSAID; and c) a disintegrant characterised in that the disintegrant comprises between about 15 to about 50% w/w based on the weight of the composition, said composition optionally comprising one or more other pharmaceutically acceptable excipients.

Abstract: Ultrasound medical gel composition, the compositions comprising: (a) a gelling agent comprising etherified hydroxyethylcellulose; (b) an antimicrobial agent, specifically the quaternary ammonium compound benzalkonium chloride; (c) a solvent, 1,3-propanediol being preferred; and (d) water.

Abstract: Compositions, products and methods including silicone based excipients are provided. The compositions, products and methods of the present invention are particularly useful for the treatment of ophthalmic diseases.

Abstract: Silicone polyethers and a process for preparation thereof wherein polyethers modified laterally with methylidene groups are reacted with hydrosiloxanes in a hydrosilylation reaction.

Abstract: The viscosity of aqueous dispersions of normally solid organic peroxides may be advantageously lowered through the use of surfactants which are polyglyceryl esters of C6-C12 fatty acids. The reduction in viscosity facilitates milling the peroxides to reduce particle size and also provides dispersions of small particle size peroxides which may be readily poured or pumped. The aqueous dispersions are useful as components of pharmaceutical, personal care, and cleaning products and the like and are effective decolorizing agents for food products, industrial products and the like.

Abstract: Disclosed herein are compositions that are useful in effecting the transdermal delivery of therapeutic agents. More particularly, the disclosed transdermal compositions may include a fatty alcohol (for example, octanol), a terpene (for example, limonene), and an active agent comprising an amine moiety.

Abstract: Stents and delivery systems with reduced chemical degradation and methods of sterilizing the same are disclosed.

Abstract: Compositions having a combination a) of one or more glycerol monoalkyl ether(s) of the general formula R—O—CH2—CHOH—CH2OH in which R is a branched or unbranched C3-C18-alkyl group, where the alkyl group can be substituted by one or more hydroxyl and/or C1-C4-alkoxy group(s) and/or the alkyl chain can be interrupted by up to four oxygen atoms, with b) an antioxidant or two or more antioxidants as stabilizer(s), the simultaneous presence of phosphocholines and phosphocholine derivatives being excluded.

Abstract: The use of biodegradable and biocompatible lactide-based nonionic amphiphiles to stabilize a model drug (salbutamol base) dispersion in hydrofluoroalkane (HFA) propellant is disclosed. The results have industrial applicability to the development of HFA-based dispersion pressurized metered-dose inhaler formulations.

Abstract: A block type organopolysiloxane is represented by the following average composition formula (1), wherein each R1 independently represents a monovalent hydrocarbon group having 1 to 12 carbons; R2 represents any of a hydrogen atom, a monovalent hydrocarbon group having 1 to 15 carbons, and a monovalent acyl group having 2 to 7 carbons; R3 represents a hydrogen atom or a monovalent hydrocarbon group having 1 to 4 carbons; X represents a divalent hydrocarbon groups having 2 to 15 carbons; “n” represents an integer of 1 or more; “m” represents an integer of 1 or more; “s” represents an integer of 0 to 100; “t” represents an integer of 0 to 50; “z” represents an integer of 0 to 50; each R4 independently represents a hydrogen atom, a hydroxyl group, an alkoxy group, or an organic group represented by the general formula (2).

Abstract: Suggested are biocide compositions, comprising (a) Esters of ethoxylated alcohols according to formula (I) R1CO(OCH2CH2)nOR2 (I) In which R1CO stands for a saturated or unsaturated acyl radical having 8 to 22 carbon atoms, R2 represents an alkyl radical having 1 to 10 carbon atoms, n denominates an integer of from 1 to 100, on condition that said esters exhibit an HLB value within a range of 10 to 17: (b) Biocides and optionally (c) Oil components or co-solvents and/or (d) Emulsifiers. The compositions show high solubility for biocides and improved emulsification properties.

Abstract: A biomimetic system is provided for use in modeling cell-cell adhesion mechanisms comprising functionalized emulsion droplets. Further, a cell culture medium and a drug delivery system using said biomimetic system are provided.

Abstract: The invention provides pharmaceutical compositions based on liquid vehicles whose density is substantially higher than that of aqueous physiological fluids. The compositions are useful as medicines in ophthalmology, in particular for the treatment of conditions affecting the posterior segment of an eye. They may be administered topically into the eye or in a minimally invasive manner by periocular injection. Preferred liquid carriers are selected from semifluorinated alkanes.

Abstract: A container and method for storing a pharmaceutical agent are provided for enhancing the storage time. The storage time of the pharmaceutical agent is improved by reducing the loss of stabilizing agents in the pharmaceutical agent. The storage container is formed from a polyolefin that includes a stabilizing agent in an amount effective to reduce or inhibit the migration of stabilizing agents in the pharmaceutical agent. The polyolefin container is formed with a fatty acid amide such as erucamide for stabilizing insulin that contains m-cresol and/or phenol as stabilizing agents for the insulin. The fatty acid amide incorporated in the container inhibits and/or reduces the rate of migration of the m-cresol and/or phenol into the polyolefin to extend the storage life of the insulin. The container can be a syringe, such as a pre-filled syringe, a storage vial or the flow path of an infusion pump.

Abstract: An oil in water microemulsion or sub-micron emulsion composition for dermal delivery of at least one pharmaceutically active ingredient, is provided. The composition includes an oil phase dispersed throughout a water phase, the oil phase including at least one member selected from the group consisting of an animal oil, a mineral oil, a vegetable oil, a silane member, a siloxane, an ester, a fatty acid, a fat, a halogen compound, and an alkoxylated alcohol; and at least one lipophilic surfactant, the water phase including at least one hydrophilic surfactant, water and optionally a non-surfactant amphiphilic compound, the weight ratio of the at least one hydrophilic surfactant to the at least one lipophilic surfactant being approximately 9.0:1.0 to 2.0:3.0.

Abstract: There is provided a liquid agrochemical composition having a stable water-diluted state, which comprises 0.5 to 30% by weight of one or more hydrophobic agrochemical active compounds, 1 to 20% by weight of one or more nonionic surfactants selected from the group consisting of a polyoxyethylene polyoxypropylene block copolymer and the like, 0 to 10% by weight of one or more anionic surfactant, 6 to 60% by weight of ?-butyrolactone, and 20 to 75% by weight of 1,3-dimethyl-2-imidazolidinone; and water-diluted solution obtained by diluting the liquid agrochemical composition with a 10 to 10,000-fold amount of water.

Abstract: As a novel compound which is excellent in odor quality and has an odor of a very clear and strong woody note, the invention provides a compound represented by the following formula (1):

Abstract: Disclosed is a liquid formulation in which a long-acting INF? conjugate that has improved in vivo duration and stability can be stored stably for a long period of time. It comprises a stabilizer comprising a buffer, a sugar alcohol, a non-ionic surfactant and an isotonic agent. Being free of human serum albumin and other potential factors harmful to the body, the liquid formulation is free of concerns about viral infections and guarantees excellent storage stability to long-acting INF? conjugates.